Xuezhu Rong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xuezhu Rong has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- En-Hua Wang
Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China
3 shared publications Xuyong Lin
Department of Pathology, College of Basic Medical Sciences and First Affiliated Hospital of China Medical University, Shenyang, China
3 shared publicationsGuiyang Jiang
Department of Pathology, College of Basic Medical Sciences and First Affiliated Hospital of China Medical University, Shenyang, China
2 shared publicationsQiang Han
Department of Pathology, College of Basic Medical Sciences and the First Affiliated Hospital of China Medical University, Shenyang, China
2 shared publications- Qiang Han
Institute of Systems Engineering, Macau University of Science and Technology, Taipa, Macao, China
2 shared publications Xiupeng Zhang
Department of Pathology, College of Basic Medical Sciences and the First Affiliated Hospital of China Medical University, Shenyang, China
2 shared publications
Latest Publications
- Open Access
- 14 December 2023
- Published by Springer Nature in Research Square
Identification of ZMIZ2 as a co-activator enhancing SIRT1 deacetylase activity in regulating Wnt and Hippo signalling pathways
Zinc finger MIZ-type containing 2 (ZMIZ2) is recognized as a ‘co-activator’ involved in embryonic development and the progression of certain malignant tumours. However, its expression and molecular mechanism in non-small cell lung cancer remain inadequately understood. Additionally, the relevant “assisted factors” of ZMIZ2 remain incompletely identified. Therefore, this study aims to investigate ZMIZ2 expression in non-small cell lung cancer tissue samples and cell lines through immunohistochemistry and immunoblotting. The goal is to establish its correlation with advanced pTNM staging, lymph node metastasis, and poor prognosis. Several in vivo and in vitro functional experiments have consistently shown that the introduction of ZMIZ2 promotes the proliferation, migration, and invasiveness of lung cancer cells, thus establishing its role as a promoter of oncogenes. Investigating the molecular mechanism, we applied mass spectrometry analysis and immunoprecipitation experiments, leading to the identification of the deacetylase Sirtuin 1 (SIRT1) as an ‘assisted key factor’ capable of interacting with ZMIZ2. Furthermore, KEGG enrichment analysis suggests that ZMIZ2 is closely related to the Wnt and Hippo pathways. Furthermore, we validated that the interaction between ZMIZ2 and SIRT1 enhances SIRT1 deacetylase activity. This direct downregulation of intranuclear β-catenin and YAP acetylation levels occurs independently of upstream proteins in the Wnt/Hippo pathways. It amplifies β-catenin-TCF4 and YAP-TEAD transcriptional activities, thereby regulating the Wnt and Hippo pathway. This results in the malignant transformation of lung cancer cells, providing a relevant experimental basis for searching for new biomarkers and the development of tumour-targeted medications.
- 14 December 2023
- Published by Springer Nature in Research Square
Open AccessIdentification of ZMIZ2 as a co-activator enhancing SIRT1 deacetylase activity in regulating Wnt and Hippo signalling pathways
Zinc finger MIZ-type containing 2 (ZMIZ2) is recognized as a ‘co-activator’ involved in embryonic development and the progression of certain malignant tumours. However, its expression and molecular mechanism in non-small cell lung cancer remain inadequately understood. Additionally, the relevant “assisted factors” of ZMIZ2 remain incompletely identified. Therefore, this study aims to investigate ZMIZ2 expression in non-small cell lung cancer tissue samples and cell lines through immunohistochemistry and immunoblotting. The goal is to establish its correlation with advanced pTNM staging, lymph node metastasis, and poor prognosis. Several in vivo and in vitro functional experiments have consistently shown that the introduction of ZMIZ2 promotes the proliferation, migration, and invasiveness of lung cancer cells, thus establishing its role as a promoter of oncogenes. Investigating the molecular mechanism, we applied mass spectrometry analysis and immunoprecipitation experiments, leading to the identification of the deacetylase Sirtuin 1 (SIRT1) as an ‘assisted key factor’ capable of interacting with ZMIZ2. Furthermore, KEGG enrichment analysis suggests that ZMIZ2 is closely related to the Wnt and Hippo pathways. Furthermore, we validated that the interaction between ZMIZ2 and SIRT1 enhances SIRT1 deacetylase activity. This direct downregulation of intranuclear β-catenin and YAP acetylation levels occurs independently of upstream proteins in the Wnt/Hippo pathways. It amplifies β-catenin-TCF4 and YAP-TEAD transcriptional activities, thereby regulating the Wnt and Hippo pathway. This results in the malignant transformation of lung cancer cells, providing a relevant experimental basis for searching for new biomarkers and the development of tumour-targeted medications.
- Open Access
- 9 April 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (4) , 1-13
WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression
WW domain binding protein-2 (WBP2) can function as a Yes-associated protein/transcriptional co-activator with PDZ-binding motif (YAP/TAZ) co-activator and has a crucial role in promoting breast cancer progression. However, the expression and potential molecular mechanisms of WBP2 in the context of lung cancer are not fully understood. We determined that WBP2 was highly expressed in lung cancer specimens and cell lines and that this expression was closely related to the advanced pTNM stage, lymph node metastasis, and poor prognosis of patients. In addition, gain- and loss-of-function experiments revealed that WBP2 could significantly promote the proliferation and invasion of lung cancer cells both in vivo and in vitro. To elucidate the underlying molecular mechanism, we determined that wild-type WBP2 could competitively bind to the WW domain of WWC3 (WW and C2 domain-containing-3) with LATS1 (Large tumor suppressor-1) through its PPxY motifs, thus inhibiting the formation of the WWC3-LATS1 complex, reducing the phosphorylation level of LATS1, suppressing the activity of the Hippo pathway, and ultimately promoting YAP nuclear translocation. Therefore, from the aspect of upstream molecules of Hippo signaling, WBP2 promotes the malignant phenotype of lung cancer cells in a unique manner that is not directly dependent upon YAP, thus providing a corresponding experimental basis for the development of targeted therapeutic drugs for lung cancer.
- 9 April 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (4) , 1-13
Open AccessWBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression
WW domain binding protein-2 (WBP2) can function as a Yes-associated protein/transcriptional co-activator with PDZ-binding motif (YAP/TAZ) co-activator and has a crucial role in promoting breast cancer progression. However, the expression and potential molecular mechanisms of WBP2 in the context of lung cancer are not fully understood. We determined that WBP2 was highly expressed in lung cancer specimens and cell lines and that this expression was closely related to the advanced pTNM stage, lymph node metastasis, and poor prognosis of patients. In addition, gain- and loss-of-function experiments revealed that WBP2 could significantly promote the proliferation and invasion of lung cancer cells both in vivo and in vitro. To elucidate the underlying molecular mechanism, we determined that wild-type WBP2 could competitively bind to the WW domain of WWC3 (WW and C2 domain-containing-3) with LATS1 (Large tumor suppressor-1) through its PPxY motifs, thus inhibiting the formation of the WWC3-LATS1 complex, reducing the phosphorylation level of LATS1, suppressing the activity of the Hippo pathway, and ultimately promoting YAP nuclear translocation. Therefore, from the aspect of upstream molecules of Hippo signaling, WBP2 promotes the malignant phenotype of lung cancer cells in a unique manner that is not directly dependent upon YAP, thus providing a corresponding experimental basis for the development of targeted therapeutic drugs for lung cancer.
- 1 October 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , 1766-1783
Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor
- 1 October 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , 1766-1783
Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor
- Open Access
- 9 October 2018
- Published by Wiley in Molecular Carcinogenesis
- Vol. 58 (1) , 126-134
CCDC85B promotes non‐small cell lung cancer cell proliferation and invasion
Coiled‐coil domain containing 85 B (CCDC85B) is involved in diverse biological processes; however, its expression patterns and functions in human cancers are yet unknown. The present study demonstrated that the expression of CCDC85B in the cytoplasm of the non‐small cell lung cancer (NSCLC) tumor cells was significantly higher compared to adjacent normal lung tissues (P < 0.05). Furthermore, CCDC85B expression correlated with advanced TNM stage (P = 0.004) and positive regional lymph node metastasis (P = 0.009) of NSCLC. In addition, in A549 and H1299 lung cancer cell lines, the overexpression of CCDC85B promoted cell proliferation and invasion, while siRNA‐mediated CCDC85B knockdown exhibited opposite effects. CCDC85B promoted AKT and GSK3β phosphorylation and upregulated the levels of active β‐catenin, Wnt targets c‐myc, cyclin D1, and MMP7. Besides, the CCDC85B‐induced upregulation of phosphorylated GSK3β and active β‐catenin was rescued following the treatment with PI3 K inhibitor, LY294002. In conclusion, CCDC85B was associated with NSCLC progression as it promoted the proliferation and invasion of lung cancer cells through activated AKT/GSK3β/β‐catenin oncogenic signaling pathway. Therefore, CCDC85B might serve as a novel target for NSCLC treatment.
- 9 October 2018
- Published by Wiley in Molecular Carcinogenesis
- Vol. 58 (1) , 126-134
Open AccessCCDC85B promotes non‐small cell lung cancer cell proliferation and invasion
Coiled‐coil domain containing 85 B (CCDC85B) is involved in diverse biological processes; however, its expression patterns and functions in human cancers are yet unknown. The present study demonstrated that the expression of CCDC85B in the cytoplasm of the non‐small cell lung cancer (NSCLC) tumor cells was significantly higher compared to adjacent normal lung tissues (P < 0.05). Furthermore, CCDC85B expression correlated with advanced TNM stage (P = 0.004) and positive regional lymph node metastasis (P = 0.009) of NSCLC. In addition, in A549 and H1299 lung cancer cell lines, the overexpression of CCDC85B promoted cell proliferation and invasion, while siRNA‐mediated CCDC85B knockdown exhibited opposite effects. CCDC85B promoted AKT and GSK3β phosphorylation and upregulated the levels of active β‐catenin, Wnt targets c‐myc, cyclin D1, and MMP7. Besides, the CCDC85B‐induced upregulation of phosphorylated GSK3β and active β‐catenin was rescued following the treatment with PI3 K inhibitor, LY294002. In conclusion, CCDC85B was associated with NSCLC progression as it promoted the proliferation and invasion of lung cancer cells through activated AKT/GSK3β/β‐catenin oncogenic signaling pathway. Therefore, CCDC85B might serve as a novel target for NSCLC treatment.
- Open Access
- 1 May 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2581-2591
WWC3 inhibits epithelial–mesenchymal transition of lung cancer by activating Hippo-YAP signaling
Background: Though we recently reported that the WWC3 inhibits the invasiveness and metastasis of lung cancer by activating the Hippo pathway, the impact and underlying mechanisms of this process still remain unclear. Methods: To identify the role of WWC3 in epithelial-mesenchymal transition of lung cancer, we performed immunohistochemistry to detect the expression levels of WWC3 and EMT-related biomarker, and analyzed their correlations in a cohort of 127 patients with NSCLC. Wound healing assay and cell invasion assay were applied to explore cell invasive ability change after WWC3 knockdown. qRT-PCR and immunoblotting were performed to assess mRNA and protein levels of EMT-related biomarkers and the main molecules changes of Hippo signaling caused by WWC3. Immunoprecipition was to examine WWC3 and LATS1 interaction. Results: WWC3 knockdown drives a pronounced shift from the epithelial to the mesenchymal phenotype in lung cancer cells. In addition, WWC3 ectopic expression in lung cancer cells attenuates mesenchymal markers and increases the epithelial markers expressions; however, WWC3-ΔWW plasmid abrogated these effects. WWC3 silencing by shRNA exerts the opposite effect. Furthermore, WWC3 levels were inversely correlated with the levels of EMT inducers (Snail and Slug) in lung cancer cells and specimens. Immunoblotting revealed that WWC3 wild-type upregulates large tumor suppressor (LATS1) and yes-associated protein (YAP) phosphorylation through its WW domain, hence activating Hippo pathway. Knockdown of YAP and LATS1, as well as the as the Verteporfin (VP) usage, could reverse this effect caused by WWC3 silencing. Conclusion: These findings suggest that WWC3 works as a tumor suppressor to inhibit EMT process and confer its candidacy as a potential therapeutic target in lung cancer.
- 1 May 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2581-2591
Open AccessWWC3 inhibits epithelial–mesenchymal transition of lung cancer by activating Hippo-YAP signaling
Background: Though we recently reported that the WWC3 inhibits the invasiveness and metastasis of lung cancer by activating the Hippo pathway, the impact and underlying mechanisms of this process still remain unclear. Methods: To identify the role of WWC3 in epithelial-mesenchymal transition of lung cancer, we performed immunohistochemistry to detect the expression levels of WWC3 and EMT-related biomarker, and analyzed their correlations in a cohort of 127 patients with NSCLC. Wound healing assay and cell invasion assay were applied to explore cell invasive ability change after WWC3 knockdown. qRT-PCR and immunoblotting were performed to assess mRNA and protein levels of EMT-related biomarkers and the main molecules changes of Hippo signaling caused by WWC3. Immunoprecipition was to examine WWC3 and LATS1 interaction. Results: WWC3 knockdown drives a pronounced shift from the epithelial to the mesenchymal phenotype in lung cancer cells. In addition, WWC3 ectopic expression in lung cancer cells attenuates mesenchymal markers and increases the epithelial markers expressions; however, WWC3-ΔWW plasmid abrogated these effects. WWC3 silencing by shRNA exerts the opposite effect. Furthermore, WWC3 levels were inversely correlated with the levels of EMT inducers (Snail and Slug) in lung cancer cells and specimens. Immunoblotting revealed that WWC3 wild-type upregulates large tumor suppressor (LATS1) and yes-associated protein (YAP) phosphorylation through its WW domain, hence activating Hippo pathway. Knockdown of YAP and LATS1, as well as the as the Verteporfin (VP) usage, could reverse this effect caused by WWC3 silencing. Conclusion: These findings suggest that WWC3 works as a tumor suppressor to inhibit EMT process and confer its candidacy as a potential therapeutic target in lung cancer.